Ken Griffin Vera Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 6,200 shares of VERA stock, worth $302,746. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,200
Previous 2,400
158.33%
Holding current value
$302,746
Previous $86,000
217.44%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding VERA
# of Institutions
184Shares Held
55.1MCall Options Held
134KPut Options Held
156K-
Avoro Capital Advisors LLC New York, NY4.31MShares$210 Million2.87% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.94MShares$192 Million0.02% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$163 Million0.0% of portfolio
-
Abingworth LLP London, X02.96MShares$145 Million19.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.79MShares$136 Million11.68% of portfolio
About Vera Therapeutics, Inc.
- Ticker VERA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,042,300
- Market Cap $1.32B
- Description
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...